Summaries of health policy coverage from major news organizations
Immune Response Corp. to Drop Study of HIV Drug Remune
Immune Response Corp. announced yesterday it will terminate a study of the HIV drug Remune, after Pfizer's Agouron Pharmaceuticalswithdrew its development partnership last month,
Bloomberg News/Los Angeles Times reports. According to Immune Response officials, the drug "wasn't meeting the study's main goal of reducing levels of HIV" in the blood, prompting Pfizer to pull back its $30 million in "milestone payments." Although Immune Response officials said that results of a Remune study being conducted in Spain "appear promising," and they plan to continue studies on their own, analysts predict that the company will experience difficulties paying for the studies without outside support. In July, Immune Response announced it had "about enough cash" to fund operations for six months. Shares of Immune Response on Nasdaq fell nine cents yesterday, to close at $2.09, after falling 44% on July 6 when Pfizer ended the partnership (Bloomberg News/Los Angeles Times, 8/31).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.